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Abstract: A beta coronavirus was identified in Wuhan, China, in December 2019 and 
was named severe acute respiratory syndrome coronavirus-2. It spread globally at 
a rapid rate and killed innumerable people. The SARS-CoV-2 infection, also called 
coronavirus disease 2019, was declared a pandemic by WHO on March 11, 2020. The 
increasing number of SARS-CoV-2 related deaths is due to a number of reasons. A few 
antiviral, antimicrobial, and immune-based drugs have been repurposed for treatment as 
well as improvement of patient prognosis. These drugs are currently being studied in 
clinical trials conducted by the World Health Organization (WHO), National Institutes 
of Health (NIH), and other global health organizations to identify the agents that 
produce maximum positive patient outcomes and reduction in mortality rate. The aim 
of this article is to discuss the safety and efficacy of the repurposed drugs in SARS- 
CoV-2 infection based on currently available clinical evidence and to emphasize the 
importance of caution required whilst employing the international therapeutic guide-
lines. Also highlighted in this article are certain specific comorbid conditions, that 
either involve treatment with the repurposed drugs or have a direct impact of the virus 
in patients owing to their vulnerability. 
Keywords: MERS, SARS-CoV-2, acute respiratory distress syndrome, cytokine storm 
syndrome, therapeutic guidelines, COVID-19
Background
Coronaviruses are a large family of viruses that predominantly reside in and 
circulate amongst animals. They can be categorized into alpha, beta, gamma, and 
delta subtypes, which together belong to the Coronaviridae family and Nidovirales 
order. The alpha and beta coronaviruses have the ability to transfer between 
animals and humans. These include the ones that induce common cold, along 
with MERS and SARS coronaviruses that cause Middle East Respiratory 
Syndrome and Severe Acute Respiratory Syndrome, respectively.1 The corona-
viruses are enveloped, containing non-segmented, positive polarized, single 
stranded RNA. They derive the name “Coronavirus” from a common feature shared 
by all of these viruses – the Spike (S) protein projecting out of the viral envelope, 
providing a crown like appearance under the electron microscope.1 The SARS 
coronavirus (SARS-CoV) that caused a serious acute viral respiratory infection 
was first reported from Asia in February 2003. More than 8,000 people contracted 
the infection with 774 deaths. SARS spread exponentially to 26 countries before it 
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was controlled within about 4 months. No SARS cases 
have been reported since 2004.2,3 Likewise, the MERS 
coronavirus (MERS-CoV) that induced a similar respira-
tory disease was first documented in September 2012 in 
Saudi Arabia, and has since spread to 27 countries, as per 
the World Health Organization reports.2 Those infected 
with MERS-CoV developed similar symptoms to SARS, 
which included cough, shortness of breath, and fever.2,3 
The World Health Organization has confirmed 2,519 cases 
of MERS and 866 deaths since its inception till date.1–3
In December 2019, an unexplained etiological pneu-
monia was identified in Wuhan, China, and was reported 
to the WHO Country Office. Subsequently, it led to the 
identification of a novel beta coronavirus (SARS-CoV-2) 
in January 2020 as the cause of the outbreak in Wuhan.4 
The infection later came to be known as coronavirus dis-
ease 2019 (COVID-19) and spread globally at a rapid rate. 
WHO announced it as a global pandemic on March 11, 
2020.4,5 Within the first 3 months of its emergence, nearly 
1 million people were afflicted and 50,000 had died.2,4–7 
The SARS-CoV-2 causes respiratory symptoms similar to 
the SARS and MERS coronaviruses. The majority of the 
infected patients experienced mild-to-moderate respiratory 
symptoms such as dry cough, fever, fatigue, and malaise, 
and they recovered with general symptomatic therapy and 
did not require intensive care. However, geriatric patients 
(age >60 years) and those with underlying medical condi-
tions like cardiovascular and renal diseases, diabetes, 
chronic respiratory disorders, cancer, hepatic syndromes, 
and the immunocompromised were found to be more 
vulnerable to developing serious life-threatening symp-
toms due to their weaker immune systems.7 As per the 
latest WHO report dated July 22, 2020, the worldwide 
number of COVID-19 cases had crossed 14 million, with 
over 600,000 deaths.8 The virus has a normal incubation 
period of 14 days from the time of exposure. However, 
most patients tend of develop symptoms within 4–5 days 
following exposure.9–11 Breathing failure from acute 
respiratory distress syndrome (ARDS) is the main cause 
of mortality in patients with COVID-19.11 Yet, recent 
evidence suggest that an immune reaction called 
“Cytokine Storm Syndrome” contributes as a secondary 
cause of death in a subgroup of patients with severe 
SARS-CoV-2 infection by inducing multiple organ failure, 
including fulminant myocarditis, leading to severe myo-
cardial damage and circulatory failure.11–14 Increased pro-
duction of rapid response inflammatory cytokines such as 
Interleukin-6, Interleukin-1β, and Tumor Necrosis Factor 
(TNF) leads to the “cytokine storm” which in turn induces 
vascular hyperpermeability, inflammation of tissues lead-
ing to multi-organ failure, and ultimately death. Hence, 
there is a growing need to suppress the high cytokine 
concentrations in COVID-19 patients who have other 
comorbid conditions and have developed an advanced 
form of the infection.12,14–16 Moreover, studies have 
shown that some of the COVID-19 patients with a poor 
prognosis have had high values in their D-dimer results. 
The possible reason for this would be the subsidiary acti-
vation of the coagulation pathway as a result of the 
immune response, which leads to the development of 
microthrombosis and disseminated intravascular 
coagulation.15–21
Guidelines for Management
The main objective of this article is to bring attention to 
the currently available therapeutic guidelines for manage-
ment of COVID-19, with a special focus on treatments 
involving the drug classes that have been repurposed to 
treat the infection. Therapeutic guidelines provided by the 
majority of the international health organizations, includ-
ing WHO and NIH, shed light on Antithrombotic Therapy, 
Immune Based Therapy, and specific Antiviral and Anti- 
Malarial drugs that have been hypothesized to produce 
promising results in COVID-19 patients.9,20,22
Antithrombotic Therapy
As discussed earlier, there is a strong association between 
COVID-19 and thrombotic events resulting from inflam-
mation and activation of coagulation pathways. This 
results in a prothrombotic state, thereby leading to an 
increase in the concentration of fibrin and fibrin degrada-
tion products, fibrinogen, and D-dimers in COVID-19 
patients.15–21 The NIH as well as WHO recommends the 
use of anticoagulants such as LMWH (enoxaparin) or 
unfractionated heparin in hospitalized COVID-19 patients 
as prophylaxis to prevent thromboembolic events, unless 
contraindicated.9,20 For cases with contraindications, the 
use of mechanical prophylaxis such as intermittent pneu-
matic compression devices is recommended.20
Immune-Based Therapy
Sufficient data is not available concerning the use of immu-
nomodulators such as interleukin-1 (eg, Anakinra) and 
interleukin-6 (eg, tocilizumab, sarilumab) inhibitors, inter-
ferons, blood derived products such as convalescent plasma 
therapy, mesenchymal stem cells (MSCs), or SARS-CoV-2 
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specific immunoglobulins.9,20,22 Interferons (α and β), 
a family of signaling proteins that are produced and released 
by host cells in response to viral activity, have been sug-
gested as a potential treatment for COVID-19 due to their 
in-vivo and in-vitro antiviral characteristics.9,20,22–24,26,27 
However, it was clearly evident from prior studies related 
to infections caused by other coronaviruses (SARS and 
MERS) that there were no significant positive outcomes in 
the patients. Furthermore, the risk of adverse events and 
toxicity caused by interferons far outweighs its 
benefit.20,23–27 Therefore, the WHO as well as NIH recom-
mend against the use of these therapeutic agents for the 
treatment of SARS-CoV-2 infection.9,20 Similarly, the use 
of Janus Kinase Inhibitors such as Baricitinib are also not 
recommended as per the therapeutic guidelines provided by 
WHO and NIH due to the enhanced immunosuppressive 
action of these drugs.9,20 JAK inhibitors exert their anti- 
inflammatory effects by inhibiting the JAK signal transdu-
cer and activation of the transcription pathway. This helps 
in ameliorating inflammatory immune responses in autoim-
mune conditions such as rheumatoid arthritis and 
interferonopathies.28,29 However, as there are not any clin-
ical data available on the efficacy of JAK inhibitors in 
COVID-19 patients, and also due to the fact that extended 
use of these drugs poses a threat of superinfection as a result 
of immunosuppression, the use of these is strongly not 
recommended.20
Other Antimicrobial and Antiviral 
Therapy
The WHO strongly recommends against the use of 
Remdesivir – the investigational antiviral drug, as well as 
others including Lopinavir, ritonavir, Umifenovir, and 
Favipiravir as treatment or prophylaxis of COVID-19. The 
same is applicable for the antimalarial drugs: chloroquine 
and hydroxychloroquine due to the inadequacy of available 
clinical data on their efficacy against the SARS-CoV-2 
virus.20 As per the remarks on WHO interim clinical man-
agement guidelines, the current scientific literature on the 
above-mentioned drugs is largely observational in nature 
and there have been very few clinical trials done to study 
the effectiveness of these agents in COVID-19 patients.20 
Also, the adverse effects induced by these agents outweigh 
the possibility of benefit.23–27,30–32 A recent update on the 
WHO website dated June 17, 2020, stated that the hydro-
xychloroquine (HCQ) phase of the Solidarity Trial to iden-
tify an effective treatment for COVID-19 has been 
discontinued based on clinical data from the Solidarity 
Trial as well as other clinical trials conducted worldwide 
including the UK’s Recovery Trial, France’s Discovery 
Trial, and a Cochrane review of other HCQ related evi-
dence. The data suggested that comparing to standard of 
care therapy, there was no significant reduction in the mor-
tality rate of hospitalized patients with SARS-CoV-2 infec-
tion when treated with HCQ.33,34 However, the preliminary 
clinical data from the randomized control trial, called the 
Adaptive COVID-19 Treatment Trial (ACTT), that was 
initiated on February 21, 2020 with 1,063 patients and 
sponsored by the National Institute of Allergy and 
Infectious Diseases (NIAID), suggested that patients receiv-
ing Remdesivir had a 31% faster recovery period than those 
receiving placebo.35 Based on this data, the NIH recom-
mends the use of the drug in hospitalized COVID-19 
patients with severe disease and extreme lung damage. 
The drug is currently available under the emergency use 
authorization of the FDA for specifically hospitalized adults 
and children with severe COVID-19 infection.9
Considerations in Special Comorbid 
Conditions
Although there are many comorbidities that could exacer-
bate the clinical condition of COVID-19 patients, this 
article focuses primarily on a few specific conditions that 
either involve treatment with the repurposed drugs dis-
cussed above or have a direct impact of the virus in 
patients owing to their vulnerability. These include hepatic 
disorders, genetic heart diseases, rheumatic autoimmune 
diseases, chronic kidney diseases, diabetes, and obesity.
Hepatic Disorders
The SARS-CoV-2 virus has a 82% resemblance to the 
genetic sequence of SARS-CoV virus and hepatic impair-
ment has been reported in up to 60% of SARS patients.37 
Moreover, the SARS-CoV-2 virus uses the angiotensin 
converting enzyme 2 (ACE 2) receptor to bind and get 
internalized into its target cells. These receptors are abun-
dantly present on the epithelial cells of hepatic and biliary 
systems. Hence, patients with SARS-CoV-2 infection are 
at increased risk of developing liver complications, espe-
cially those who have preexisting liver problems.38,39 The 
latest report from the European Association for the Study 
of the Liver (EASL) and European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID) provides 
guidelines on the safety of the above discussed repurposed 
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investigational drugs on COVID-19 patients with preexist-
ing liver conditions or transplantations.40 Patients who 
undergo liver transplantations are most likely to develop 
severe infection due to the immunosuppressive agents. The 
same is applicable for patients with liver carcinomas and 
undergoing radiation/chemotherapy. It is crucial to con-
sider the drug–drug interactions between the COVID-19 
investigational medications and those that are already 
being used to treat the patient’s preexisting 
condition.36,38,40 The EASL-ESCMID position paper 
recommends that COVID-19 patients with liver disease 
and risk factors for development of severe infection must 
be started on an early antiviral therapy program or enrolled 
in clinical trials at various COVID-19 specific healthcare 
centers.40 This recommendation is based on the fact that 
early initiation of antiviral treatment has shortened the 
course of other viral infections such as influenza. Thus, it 
might be beneficial in patients suffering from SARS-CoV 
-2 infection as well. Nevertheless, appropriate dose adjust-
ments are required based on the functioning capacity of 
the liver, identified from the patient’s Child-Pugh score. It 
is also imperative to carefully monitor for adverse events 
and toxicities.38,40
Genetic Heart Diseases
It is discernible that genetic heart diseases are relatively 
rare amongst populations and SARS-CoV-2 is a newly 
discovered virus. Hence, scientific data about the best 
clinical practice in this area is limited. Nevertheless, the 
Cardiac Society of Australia and New Zealand (CSANZ) 
has provided a few recommendations in their recent con-
sensus statement to effectively manage COVID-19 
patients with genetic heart diseases. As per this statement, 
patients with congenital structural cardiac problems are 
recommended to continue their cardiovascular drugs such 
as beta blockers, Angiotensin Converting Enzyme 
Inhibitors (ACEIs), Angiotensin Receptor Blockers 
(ARBs), Calcium Channel Blockers (CCBs), etc.41 There 
have been conflicting opinions about the safety of ACEIs 
and ARBs in SARS-CoV-2 patients due to the binding site 
of the virus on ACE 2 receptors that are found on the cell 
membranes of renal tissue as well as the epithelial cells of 
the GI tract and lungs. A few preclinical studies have 
demonstrated that prolonged use of ACEIs/ARBs upregu-
lates the expression of ACE 2 receptor, thereby causing 
healthcare professionals combating the infection and lead-
ing research scientists to question the possibility of these 
drugs posing a threat of exacerbating the SARS-CoV-2 
infection.39,42–47 However, as these concerns are largely 
theoretical in nature and there are not any relevant clinical 
trials or other sufficient evidence to substantiate this, inter-
national organizations focusing on cardiovascular medi-
cine recommend the continuation of the patients’ regular 
cardiac medications.41–46 Moreover, a recent cohort study 
showed that the use of ACEIs/ARBs has been associated 
with significantly improved survival rates amongst hospi-
talized hypertensive patients with SARS-CoV-2 
infection.47 It is also imperative to consult a specialist 
cardiologist in genetic heart diseases prior to initiating 
atypical-repurposed drugs discussed above or enrolling in 
clinical trials involving these drugs in patients coinfected 
with SARS-CoV-2 infection.41
Rheumatic Autoimmune Diseases
The American College of Rheumatology Guidelines 
recommend continuing the use of regular antirheumatic 
drugs in COVID-19 patients suffering from preexisting 
rheumatic conditions. This includes the use of ACEI/ 
ARB for scleroderma renal crisis or SLE, due to the 
protective effects of these drugs on the kidneys.48–51 As 
for NSAIDs, it was recommended in the guidelines to use 
them with caution in newly diagnosed rheumatic disor-
ders; nonetheless stop if patients develop severe SARS- 
CoV-2 infection due to the poor prognosis resulting from 
the cardiac, kidney, and liver injury that have been asso-
ciated to COVID-19 as severe manifestations of the 
infection.38,40,41,48,49,52 In the case of Glucocorticoid ther-
apy, there has been conflicting evidence in favor of their 
use in COVID-19 patients. Emerging data indicate that 
their anti-inflammatory properties could potentially mini-
mize the impact of SARS-CoV-2 infection, especially in 
its late stages which is characterized by cytokine storm 
and hyperinflammation.48,53,54 However, these are very 
limited data to support the use of glucocorticoids in 
SARS-CoV-2 infected patients given the risk of glucocor-
ticoid induced immunosuppression, leading to opportunis-
tic infections. Moreover, the plethora of evidence available 
in support of the detrimental effects of glucocorticoids 
contradict the limited evidence in support of their benefi-
cial effects. Hence, the guidelines recommend continuing 
standard of care treatment using the lowest effective doses 
of glucocorticoids drugs and avoiding sudden termination 
of therapy in patients with underlying rheumatic disease. 
However, it was also acknowledged by the guidelines 
panel that higher doses may be required in cases of ser-
ious, life-threatening situations with vital organ damage 
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even after exposure to SARS-CoV-2.48 Moreover, an 
update from the UK’s Recovery Trial has demonstrated 
that Dexamethasone, a synthetic glucocorticoid agent, 
could save the lives of critically ill patients with SARS- 
CoV-2 infection. Treatment with the agent showed about 
one-third reduction in mortality for patients on ventilators 
whilst for those requiring only oxygen the mortality rate 
was reduced by about one-fifth.55
The panel recommends continuation/initiation of 
Conventional Synthetic disease-modifying antirheumatic 
drugs (csDMARDs) when required regardless of whether 
the patient has been exposed to SARS–CoV-2 infection or 
not. This recommendation was formed based on the fact 
that risk of severe infection with these drugs is consider-
ably lower, especially when administered as 
monotherapy.48,56,57 Nevertheless, caution must be exer-
cised due to the known adverse effects of these drugs such 
as diarrhea and other gastrointestinal manifestations, hepa-
titis, cytopenia, and cardiotoxicity which could be misin-
terpreted with symptoms of SARS-CoV-2 infection.48 
Likewise, due to lack of sufficient randomized controlled 
trials data to support sustained use, the panel recom-
mended that all immunomodulators, immunosuppressants, 
and JAK inhibitors be temporarily withheld or discontin-
ued in the light of reported or suspected SARS-CoV-2 
infection.48
Chronic Kidney Diseases
The NICE COVID-19 rapid guideline for CKD recommends 
the continuation of regular medications including ACEI/ 
ARB, diuretics, and immunosuppressants in patients under-
lying kidney disease exhibiting symptoms of SARS-CoV-2 
infection. Dose reduction and therapeutic dose monitoring 
have been recommended by the Renal Association Guidance 
for patients on immunosuppressants, corticosteroids, and 
anti-cancer drugs such as cyclophosphamide.58,59 This is 
particularly applicable for patients on the “Induction” 
phase. Immunosuppressive medications should be assessed 
on a case-by-case basis, balancing the risk of insufficient 
therapy or acute relapse against the risk of SARS-CoV-2 
infection affecting a particular patient.59 Abrupt cessation 
of corticosteroid maintenance therapy is deemed detrimental 
to patients with autoimmune kidney disease due to risk of 
relapses and thereby not recommended. In patients under 
maintenance regimens with biologics such as LA- 
Rituximab, delayed time interval between infusions is 
recommended, if the risk of disease flare is less and the 
likelihood of severe manifestations of SARS-CoV-2 
infection is more.59 Non-Steroidal Anti-inflammatory 
Drugs (NSAIDs) are to be avoided in patients with both 
acute as well as chronic kidney diseases. Patients exhibiting 
flu symptoms are to be treated with acetaminophen (para-
cetamol). As for patients preparing for renal transplant, the 
procedure or immunosuppression must not be initiated unless 
the SARS-CoV-2 nasopharyngeal swab test result is 
negative.60 Lastly, dialysis following transplantation must 
be done in a COVID-19 secure area after having taken 
precautionary safety measures.58–60
Diabetes and Obesity
Based on recent evidence, it is known that both diabetes and 
obesity are related to severe complications in SARS-CoV-2 
infection.61 Epidemiological findings from regions severely 
affected by SARS-CoV-2, along with CDC reports have 
shown that the risk of mortality due to COVID-19 is approxi-
mately 50% greater in diabetic patients.61,62 Likewise, hos-
pitalized COVID-19 patients who were overweight or obese 
with a body mass index (BMI) of greater than 25 kg/m2 were 
at increased risk of requiring mechanical ventilation.63 There 
is a strong association between insulin resistance and visceral 
adipose tissue (VAT) that are abundantly present in obese 
patients. The adipocytes secreted most of the inflammatory 
and coagulopathic molecules including TNF-α and interleu-
kin-6, relating to the SARS-CoV-2 induced cytokine 
storm.63–65 Evidence suggests that Type-2 diabetic patients 
had increased levels of TNF-α.63,66 Moreover, individuals 
with both the comorbidities had lower levels of Interleukin- 
10 (IL-10), which is a protective anti-inflammatory 
cytokine.63,67 Hence, obese patients with Type 2 diabetes 
mellitus are at a significantly increased risk of developing 
a severe form of SARS-CoV-2 infection.63,68,69
A few retrospective observational studies have sug-
gested the use of Metformin, the first line therapeutic 
agent for Type-2 diabetes mellitus, to mitigate the impact 
of SARS-CoV-2 infection in diabetic and obese patients. It 
was found that metformin decreased the levels of IL-6, 
TNF-α, and increased the levels of IL-10.63,70 Over the 
years, metformin has been used for treatment of various 
diseases apart from type-2 diabetes. It is used as an off-label 
medication for weight loss in the USA.68,71 Furthermore, 
findings from a retrospective cohort study demonstrated that 
early administration of metformin is associated with sub-
stantially lower mortality in geriatric patients with 
pneumonia.68,72 Since elderly patients are at increased risk 
of mortality due to SARS-CoV-2, it would be appropriate to 
consider incorporation of metformin as an adjuvant agent 
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for treatment of the infection.68,73 Other beneficial effects of 
metformin in minimizing the impact of SARS-CoV-2 
include reduced macrophage cytokine synthesis, increased 
insulin sensitivity, and activation of AMP-activated protein 
kinase (AMPK).63,68,70,71 Lastly, metformin has also been 
hypothesized to possess a viral inhibitory capability through 
increasing insulin sensitivity.68,74 Therefore, it is plausible 
to consider metformin as an effective therapeutic agent for 
management of COVID-19 in obese, diabetic, and geriatric 
patients. However, there is a need for further research into 
this topic and, due to the lack of sufficient data from clinical 
trials, the efficacy of Metformin in SARS-CoV-2 remains to 
be validated.
Conclusion
At present, limited clinical data is available to substantiate 
the beneficial effects of repurposed drugs on SARS-CoV-2 
patients. The clinical guidelines highlighted above have been 
made to provide optimal care during the prevailing pandemic 
situation. Hence, due to the evolving nature of literature as 
a result of ongoing research to identify the best possible 
therapeutic agents to combat the infection, frontline health 
professionals are recommended to keep a close watch for 
recent updates to the guidelines based on clinical trial results. 
Furthermore, when patients with serious underlying comor-
bid conditions contract SARS-CoV-2 infection, it is impera-
tive that the specialist physician involved in the treatment of 
their underlying condition is also included in the healthcare 
team treating the infection. This is particularly important for 
making crucial decisions such as enrolment of patients in 
clinical trials involving repurposed drugs, initiating the drugs 
as pre-/post-exposure prophylaxis, and dose alterations as 
necessitated by standard of care therapeutic guidelines for 
the patients’ underlying disease.
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